STOCK TITAN

[8-K] Aimei Health Technology Co., Ltd Unit Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Karpus Management, Inc. filed Amendment No. 2 to Schedule 13G for Eureka Acquisition Corp (EURKU) covering the event date 30 June 2025.

The registered investment adviser now reports beneficial ownership of 327,400 common shares, representing 4.28 % of the outstanding class. Karpus holds sole voting and dispositive power over the entire position and no shared power with other parties. Because the stake has fallen below the 5 % threshold, Karpus is no longer deemed a 5 % beneficial owner under Section 13(d) of the Exchange Act but remains subject to Rule 13d-1(b) reporting requirements.

The shares are held in discretionary advisory accounts managed by Karpus, which operates independently of its parent, City of London Investment Group plc, through established informational barriers. The filing affirms that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.

Implications for investors: the reduction slightly increases EURKU’s public float and removes Karpus from the list of significant 5 % holders, potentially diminishing expectations of activist involvement. Nonetheless, a 4.28 % position remains a meaningful minority interest that could provide ongoing institutional oversight.

Karpus Management, Inc. ha presentato l'Emendamento n. 2 al Modulo 13G per Eureka Acquisition Corp (EURKU) relativo alla data dell'evento del 30 giugno 2025.

Il consulente d'investimento registrato segnala ora una partecipazione effettiva di 327.400 azioni ordinarie, che rappresentano il 4,28% della classe in circolazione. Karpus detiene il potere esclusivo di voto e di disposizione sull'intera posizione e nessun potere condiviso con altre parti. Poiché la quota è scesa al di sotto della soglia del 5%, Karpus non è più considerato un detentore effettivo del 5% ai sensi della Sezione 13(d) del Exchange Act, ma rimane soggetto agli obblighi di segnalazione previsti dalla Regola 13d-1(b).

Le azioni sono detenute in conti discrezionali di consulenza gestiti da Karpus, che opera in modo indipendente dalla sua controllante, City of London Investment Group plc, attraverso barriere informative stabilite. La comunicazione conferma che i titoli sono stati acquisiti nell'ordinaria attività commerciale e non con l'intento di influenzare il controllo dell'emittente.

Implicazioni per gli investitori: la riduzione aumenta leggermente il flottante pubblico di EURKU e rimuove Karpus dall'elenco dei detentori significativi del 5%, potenzialmente riducendo le aspettative di un coinvolgimento attivista. Tuttavia, una posizione del 4,28% rimane un interesse di minoranza significativo che potrebbe garantire una supervisione istituzionale continua.

Karpus Management, Inc. presentó la Enmienda Nº 2 al Formulario 13G para Eureka Acquisition Corp (EURKU) correspondiente a la fecha del evento 30 de junio de 2025.

El asesor de inversiones registrado informa ahora una propiedad beneficiosa de 327.400 acciones comunes, que representan el 4,28 % de la clase en circulación. Karpus mantiene el poder exclusivo de voto y disposición sobre toda la posición y no comparte poder con otras partes. Debido a que la participación ha caído por debajo del umbral del 5 %, Karpus ya no se considera un propietario beneficioso del 5 % según la Sección 13(d) de la Ley de Intercambio, pero sigue sujeto a los requisitos de reporte de la Regla 13d-1(b).

Las acciones se mantienen en cuentas discrecionales de asesoría gestionadas por Karpus, que opera de forma independiente de su matriz, City of London Investment Group plc, a través de barreras informativas establecidas. La presentación afirma que los valores se adquirieron en el curso ordinario del negocio y no con el propósito de influir en el control del emisor.

Implicaciones para los inversores: la reducción aumenta ligeramente el flotante público de EURKU y elimina a Karpus de la lista de titulares significativos del 5 %, lo que podría disminuir las expectativas de una participación activista. No obstante, una posición del 4,28 % sigue siendo un interés minoritario relevante que podría proporcionar supervisión institucional continua.

Karpus Management, Inc.는 2025년 6월 30일 기준 Eureka Acquisition Corp (EURKU)에 대한 Schedule 13G 수정서 2호를 제출했습니다.

등록된 투자 자문사는 현재 327,400주의 보통주 실질 소유권을 보고하며, 이는 발행 주식의 4.28%에 해당합니다. Karpus는 전체 지분에 대해 단독 의결권 및 처분권을 보유하고 있으며, 다른 당사자와는 공동 권한이 없습니다. 지분이 5% 기준선 아래로 떨어짐에 따라 Karpus는 더 이상 Exchange Act 13(d)조에 따른 5% 실질 소유주로 간주되지 않지만, Rule 13d-1(b) 보고 요건은 계속 준수합니다.

주식은 Karpus가 관리하는 재량 자문 계좌에 보유되어 있으며, Karpus는 모회사인 City of London Investment Group plc와는 독립적으로 운영되며 정보 장벽이 구축되어 있습니다. 제출 서류는 증권이 정상적인 사업 과정에서 취득되었으며 발행사의 지배권에 영향을 미치기 위한 목적이 아님을 확인합니다.

투자자에 대한 시사점: 이번 감소로 EURKU의 공개 유통 주식 수가 다소 증가하고 Karpus는 5% 이상 주요 보유자 명단에서 제외되어 행동주의 개입에 대한 기대가 줄어들 수 있습니다. 그럼에도 불구하고 4.28% 지분은 계속해서 중요한 소수 지분으로, 지속적인 기관 감시 역할을 할 수 있습니다.

Karpus Management, Inc. a déposé l'amendement n° 2 au formulaire 13G concernant Eureka Acquisition Corp (EURKU) pour la date de l'événement du 30 juin 2025.

Le conseiller en investissement enregistré déclare désormais une possession bénéficiaire de 327 400 actions ordinaires, représentant 4,28 % de la classe en circulation. Karpus détient le pouvoir exclusif de vote et de disposition sur l'intégralité de la position et aucun pouvoir partagé avec d'autres parties. Étant donné que la participation est tombée en dessous du seuil de 5 %, Karpus n'est plus considéré comme un détenteur bénéficiaire à 5 % selon la Section 13(d) du Exchange Act, mais reste soumis aux obligations de déclaration de la Règle 13d-1(b).

Les actions sont détenues dans des comptes-conseils discrétionnaires gérés par Karpus, qui opère indépendamment de sa société mère, City of London Investment Group plc, grâce à des barrières informationnelles établies. Le dépôt confirme que les titres ont été acquis dans le cours normal des affaires et non dans le but d'influencer le contrôle de l'émetteur.

Implications pour les investisseurs : cette réduction augmente légèrement le flottant public d'EURKU et retire Karpus de la liste des détenteurs significatifs à 5 %, ce qui pourrait réduire les attentes d'une implication activiste. Néanmoins, une position de 4,28 % reste une participation minoritaire significative pouvant assurer une surveillance institutionnelle continue.

Karpus Management, Inc. hat die Änderung Nr. 2 zum Schedule 13G für Eureka Acquisition Corp (EURKU) mit dem Ereignisdatum 30. Juni 2025 eingereicht.

Der registrierte Anlageberater meldet nun wirtschaftliches Eigentum an 327.400 Stammaktien, was 4,28 % der ausstehenden Aktienklasse entspricht. Karpus hält alleinige Stimm- und Verfügungsgewalt über die gesamte Position und keine geteilte Macht mit anderen Parteien. Da der Anteil unter die 5 %-Schwelle gefallen ist, gilt Karpus nicht mehr als 5 %-Eigentümer gemäß Abschnitt 13(d) des Exchange Act, unterliegt aber weiterhin den Meldepflichten nach Regel 13d-1(b).

Die Aktien werden in diskretionären Beratungskonten gehalten, die von Karpus verwaltet werden, das unabhängig von seiner Muttergesellschaft, der City of London Investment Group plc, durch etablierte Informationsbarrieren operiert. Die Meldung bestätigt, dass die Wertpapiere im normalen Geschäftsverlauf erworben wurden und nicht mit dem Ziel, die Kontrolle über den Emittenten zu beeinflussen.

Auswirkungen für Investoren: Die Reduzierung erhöht leicht den Streubesitz von EURKU und entfernt Karpus von der Liste signifikanter 5 %-Inhaber, was Erwartungen an aktiven Einfluss verringern könnte. Dennoch bleibt eine Position von 4,28 % ein bedeutendes Minderheitsinteresse, das eine fortlaufende institutionelle Überwachung ermöglichen kann.

Positive
  • Enhanced transparency: Updated 13G/A provides investors with clear, timely data on institutional ownership.
Negative
  • Stake falls below 5 %: Karpus’ reduction removes a significant holder, hinting at recent sales and slightly diluting concentrated ownership.

Insights

TL;DR – Karpus drops to 4.28 %, exiting 5 % holder status; governance impact modest.

The amendment shows Karpus’ stake now sits below the critical 5 % reporting threshold, signalling recent selling. While this reduces the probability of an activist campaign, Karpus retains sole voting control over a still-material block that can influence routine matters. The certification that shares are held in the ordinary course, plus independent control from its parent CLIG, further limits governance implications. Overall, the filing is more administrative than strategic but worth noting for ownership-structure tracking.

TL;DR – Slightly negative signal: institutional holder trims position, float rises.

For a SPAC like EURKU, concentrated holdings can support price stability. Karpus’ reduction to 4.28 % adds incremental liquidity but may introduce mild selling pressure if the exit continues. Absence of intent to influence control suggests no near-term catalyst from this shareholder. Market impact should be limited unless further divestiture emerges.

Karpus Management, Inc. ha presentato l'Emendamento n. 2 al Modulo 13G per Eureka Acquisition Corp (EURKU) relativo alla data dell'evento del 30 giugno 2025.

Il consulente d'investimento registrato segnala ora una partecipazione effettiva di 327.400 azioni ordinarie, che rappresentano il 4,28% della classe in circolazione. Karpus detiene il potere esclusivo di voto e di disposizione sull'intera posizione e nessun potere condiviso con altre parti. Poiché la quota è scesa al di sotto della soglia del 5%, Karpus non è più considerato un detentore effettivo del 5% ai sensi della Sezione 13(d) del Exchange Act, ma rimane soggetto agli obblighi di segnalazione previsti dalla Regola 13d-1(b).

Le azioni sono detenute in conti discrezionali di consulenza gestiti da Karpus, che opera in modo indipendente dalla sua controllante, City of London Investment Group plc, attraverso barriere informative stabilite. La comunicazione conferma che i titoli sono stati acquisiti nell'ordinaria attività commerciale e non con l'intento di influenzare il controllo dell'emittente.

Implicazioni per gli investitori: la riduzione aumenta leggermente il flottante pubblico di EURKU e rimuove Karpus dall'elenco dei detentori significativi del 5%, potenzialmente riducendo le aspettative di un coinvolgimento attivista. Tuttavia, una posizione del 4,28% rimane un interesse di minoranza significativo che potrebbe garantire una supervisione istituzionale continua.

Karpus Management, Inc. presentó la Enmienda Nº 2 al Formulario 13G para Eureka Acquisition Corp (EURKU) correspondiente a la fecha del evento 30 de junio de 2025.

El asesor de inversiones registrado informa ahora una propiedad beneficiosa de 327.400 acciones comunes, que representan el 4,28 % de la clase en circulación. Karpus mantiene el poder exclusivo de voto y disposición sobre toda la posición y no comparte poder con otras partes. Debido a que la participación ha caído por debajo del umbral del 5 %, Karpus ya no se considera un propietario beneficioso del 5 % según la Sección 13(d) de la Ley de Intercambio, pero sigue sujeto a los requisitos de reporte de la Regla 13d-1(b).

Las acciones se mantienen en cuentas discrecionales de asesoría gestionadas por Karpus, que opera de forma independiente de su matriz, City of London Investment Group plc, a través de barreras informativas establecidas. La presentación afirma que los valores se adquirieron en el curso ordinario del negocio y no con el propósito de influir en el control del emisor.

Implicaciones para los inversores: la reducción aumenta ligeramente el flotante público de EURKU y elimina a Karpus de la lista de titulares significativos del 5 %, lo que podría disminuir las expectativas de una participación activista. No obstante, una posición del 4,28 % sigue siendo un interés minoritario relevante que podría proporcionar supervisión institucional continua.

Karpus Management, Inc.는 2025년 6월 30일 기준 Eureka Acquisition Corp (EURKU)에 대한 Schedule 13G 수정서 2호를 제출했습니다.

등록된 투자 자문사는 현재 327,400주의 보통주 실질 소유권을 보고하며, 이는 발행 주식의 4.28%에 해당합니다. Karpus는 전체 지분에 대해 단독 의결권 및 처분권을 보유하고 있으며, 다른 당사자와는 공동 권한이 없습니다. 지분이 5% 기준선 아래로 떨어짐에 따라 Karpus는 더 이상 Exchange Act 13(d)조에 따른 5% 실질 소유주로 간주되지 않지만, Rule 13d-1(b) 보고 요건은 계속 준수합니다.

주식은 Karpus가 관리하는 재량 자문 계좌에 보유되어 있으며, Karpus는 모회사인 City of London Investment Group plc와는 독립적으로 운영되며 정보 장벽이 구축되어 있습니다. 제출 서류는 증권이 정상적인 사업 과정에서 취득되었으며 발행사의 지배권에 영향을 미치기 위한 목적이 아님을 확인합니다.

투자자에 대한 시사점: 이번 감소로 EURKU의 공개 유통 주식 수가 다소 증가하고 Karpus는 5% 이상 주요 보유자 명단에서 제외되어 행동주의 개입에 대한 기대가 줄어들 수 있습니다. 그럼에도 불구하고 4.28% 지분은 계속해서 중요한 소수 지분으로, 지속적인 기관 감시 역할을 할 수 있습니다.

Karpus Management, Inc. a déposé l'amendement n° 2 au formulaire 13G concernant Eureka Acquisition Corp (EURKU) pour la date de l'événement du 30 juin 2025.

Le conseiller en investissement enregistré déclare désormais une possession bénéficiaire de 327 400 actions ordinaires, représentant 4,28 % de la classe en circulation. Karpus détient le pouvoir exclusif de vote et de disposition sur l'intégralité de la position et aucun pouvoir partagé avec d'autres parties. Étant donné que la participation est tombée en dessous du seuil de 5 %, Karpus n'est plus considéré comme un détenteur bénéficiaire à 5 % selon la Section 13(d) du Exchange Act, mais reste soumis aux obligations de déclaration de la Règle 13d-1(b).

Les actions sont détenues dans des comptes-conseils discrétionnaires gérés par Karpus, qui opère indépendamment de sa société mère, City of London Investment Group plc, grâce à des barrières informationnelles établies. Le dépôt confirme que les titres ont été acquis dans le cours normal des affaires et non dans le but d'influencer le contrôle de l'émetteur.

Implications pour les investisseurs : cette réduction augmente légèrement le flottant public d'EURKU et retire Karpus de la liste des détenteurs significatifs à 5 %, ce qui pourrait réduire les attentes d'une implication activiste. Néanmoins, une position de 4,28 % reste une participation minoritaire significative pouvant assurer une surveillance institutionnelle continue.

Karpus Management, Inc. hat die Änderung Nr. 2 zum Schedule 13G für Eureka Acquisition Corp (EURKU) mit dem Ereignisdatum 30. Juni 2025 eingereicht.

Der registrierte Anlageberater meldet nun wirtschaftliches Eigentum an 327.400 Stammaktien, was 4,28 % der ausstehenden Aktienklasse entspricht. Karpus hält alleinige Stimm- und Verfügungsgewalt über die gesamte Position und keine geteilte Macht mit anderen Parteien. Da der Anteil unter die 5 %-Schwelle gefallen ist, gilt Karpus nicht mehr als 5 %-Eigentümer gemäß Abschnitt 13(d) des Exchange Act, unterliegt aber weiterhin den Meldepflichten nach Regel 13d-1(b).

Die Aktien werden in diskretionären Beratungskonten gehalten, die von Karpus verwaltet werden, das unabhängig von seiner Muttergesellschaft, der City of London Investment Group plc, durch etablierte Informationsbarrieren operiert. Die Meldung bestätigt, dass die Wertpapiere im normalen Geschäftsverlauf erworben wurden und nicht mit dem Ziel, die Kontrolle über den Emittenten zu beeinflussen.

Auswirkungen für Investoren: Die Reduzierung erhöht leicht den Streubesitz von EURKU und entfernt Karpus von der Liste signifikanter 5 %-Inhaber, was Erwartungen an aktiven Einfluss verringern könnte. Dennoch bleibt eine Position von 4,28 % ein bedeutendes Minderheitsinteresse, das eine fortlaufende institutionelle Überwachung ermöglichen kann.

false 0001979005 0001979005 2025-07-06 2025-07-06 0001979005 AFJK:OrdinarySharesParValue0.0001PerShareMember 2025-07-06 2025-07-06 0001979005 AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember 2025-07-06 2025-07-06 0001979005 AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember 2025-07-06 2025-07-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

July 6, 2025

Date of Report (Date of earliest event reported)

 

AIMEI HEALTH TECHNOLOGY CO., LTD

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-41880   N/A
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

  (I.R.S. Employer
Identification No.)

 

10 East 53rd Street, Suite 3001

New York, NY

  10022
(Address of Principal Executive Offices)   (Zip Code)

 

86-13758131392

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share   AFJK   The Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary Share   AFJKR   The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one Right   AFJKU   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

Extension of the Termination Date

 

An aggregate of $150,000 (the “Extension Payment”) has been deposited into the trust account of Aimei Health Technology Co., Ltd (the “Company”) for its public shareholders, which enables the Company to further extend the period of time it has to consummate its initial business combination by one month (the “Extension”) from July 6, 2025 to August 6, 2025 (the “Termination Date”). The Extension is the eighth of up to 12 extensions permitted under the Amended and Restated Articles of Association of the Company currently in effect.

 

Promissory Note

 

In connection with the Extension, the Company issued, on July 6, 2025  , an unsecured promissory note in the total principal amount of $150,000 (the “Promissory Note”) to Aimei Health Ltd, a Cayman Islands exempted company (the “Sponsor”) and United Hydrogen Group Inc., an exempted company with limited liability incorporated in the Cayman Islands (“United Hydrogen,” and together with the Sponsor, the “Payees”). The amount was equally divided between the Payees, with each contributing $75,000, to fund the Extension Payment. The Promissory Note does not bear interest and the principal thereunder becomes due and payable upon the date on which the Company consummates a business combination with United Hydrogen (the “Business Combination”). The Payees have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company, at a price of $10.00 per unit, each consisting of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share of the Company, immediately prior to the consummation of the Business Combination, by providing the Company with written notices of their intention to convert the Promissory Note at least two business days prior to the closing of the Business Combination.

 

The foregoing description of the Promissory Note is not complete and is qualified in its entirety by reference to the text of such document, which is filed as Exhibit 10.1 hereto and which is incorporated herein by reference.

 

Item 9.01 Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Promissory Note, dated July 6, 2025, by and among Aimei Health Technology Co., Ltd, Aimei Health Ltd, and United Hydrogen Group Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 7, 2025

 

  Aimei Health Technology Co., Ltd
     
  By: /s/ Junheng Xie
  Name: Junheng Xie
  Title: Chief Executive Officer and Director
    (Principal Executive Officer)

 

 

 

FAQ

How many Eureka Acquisition Corp (EURKU) shares does Karpus Management own?

Karpus reports beneficial ownership of 327,400 common shares.

What percentage of EURKU’s outstanding shares does this represent?

The stake equals 4.28 % of the outstanding common stock.

Does Karpus share voting or dispositive power over these shares?

No. The adviser holds sole voting and dispositive power and reports 0 % shared power.

Under which SEC rule is the Schedule 13G/A filed?

The filing is made pursuant to Rule 13d-1(b) for registered investment advisers.

What is the significance of falling below the 5 % ownership threshold?

Below 5 %, Karpus is no longer a statutory 5 % holder, reducing regulatory obligations and potential influence on control matters.
Aimei Health Technology Co., Ltd

NASDAQ:AFJKU

AFJKU Rankings

AFJKU Latest News

AFJKU Stock Data

5.67M
5.53%
0.05%
Shell Companies
Blank Checks
United States
NEW YORK